Brain Switches Could Clear Alzheimer's Plaques Safely

Scientists found a way to flip the brain's natural switches to clear away the sticky plaques that cause Alzheimer's disease.

Researchers at Sweden's Karolinska Institutet and Japan's RIKEN Center for Brain Science identified two brain receptors that control how effectively the brain breaks down amyloid beta. These harmful protein clumps form plaques that destroy memory in over 6 million Americans living with Alzheimer's.

The team discovered that receptors called SST1 and SST4 work together to regulate neprilysin, an enzyme that naturally clears amyloid beta from the brain. As we age, neprilysin levels drop, allowing dangerous plaques to accumulate in the memory center of our brains.

When scientists tested mice without these receptors, neprilysin levels plummeted. The mice developed memory problems and accumulated the same plaques seen in human Alzheimer's patients.

But here's where it gets exciting. The researchers created a compound that activates both SST1 and SST4 receptors in mice with Alzheimer's-like symptoms.

The results were remarkable. Stimulating these receptors boosted neprilysin levels, reduced plaque buildup, and improved the mice's memory function without causing serious side effects.

"Our findings show that the brain's own defense against amyloid beta can be strengthened by stimulating these receptors," says Per Nilsson, a researcher at Karolinska Institutet.

Why This Inspires

Current Alzheimer's antibody treatments cost tens of thousands of dollars per year and can trigger dangerous brain swelling or bleeding in some patients. Many families simply can't afford them, and others must weigh devastating side effects against potential benefits.

This discovery points toward a completely different approach. SST1 and SST4 belong to a receptor family that responds well to small molecule drugs, the kind that can be manufactured cheaply and taken as simple pills.

"If we can develop small molecules that pass the blood-brain barrier, our hope is that we will be able to treat the disease at a significantly lower cost and without serious side effects," Nilsson explains.

These receptors are already well understood by pharmaceutical companies because they're common drug targets. That familiarity could speed up the development process considerably.

The international collaboration brings together expertise from multiple universities and received funding from organizations including the Swedish Research Council and the Alzheimer's Foundation. The researchers reported no conflicts of interest.

While human trials still lie ahead, the study offers something families touched by Alzheimer's desperately need: a genuinely new path forward that's both scientifically sound and potentially accessible to everyone who needs it.